# Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct01930188` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01930188](<https://clinicaltrials.gov/study/NCT01930188>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01930188

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1231 participants.

## Technical summary

Registry record NCT01930188. Randomized; double masking; primary purpose treatment. Start 2013-12-02 (actual); primary completion 2015-10-12 (actual). Results posted on 2019-01-07.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1231 participants (enrolled count; ClinicalTrials.gov record NCT01930188, source copy `cardio:ctgov-nct01930188-2019-06-13`, retrieved 2026-10-26)
- Started: 2013-12-02 (actual) (ClinicalTrials.gov record NCT01930188, source copy `cardio:ctgov-nct01930188-2019-06-13`, retrieved 2026-10-26)
- Primary completion: 2015-10-12 (actual) (ClinicalTrials.gov record NCT01930188, source copy `cardio:ctgov-nct01930188-2019-06-13`, retrieved 2026-10-26)
- Completion: 2015-10-12 (actual) (ClinicalTrials.gov record NCT01930188, source copy `cardio:ctgov-nct01930188-2019-06-13`, retrieved 2026-10-26)
- Results first posted: 2019-01-07 (ClinicalTrials.gov record NCT01930188, source copy `cardio:ctgov-nct01930188-2019-06-13`, retrieved 2026-10-26)
- Countries: Argentina; Bulgaria; Czechia; Hong Kong SAR China; Hungary; India; Japan; Mexico; Norway; Portugal; Romania; Russia; South Africa; Spain; Sweden; Thailand; Türkiye; Ukraine (ClinicalTrials.gov record NCT01930188, source copy `cardio:ctgov-nct01930188-2019-06-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01930188-2019-06-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes
- Acronym: SUSTAIN™ 2
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): semaglutide
- Intervention (Drug): sitagliptin
- Intervention (Drug): placebo
- Intervention (Drug): placebo
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial (`cardio:pubmed-28385659`)
- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials (`cardio:pubmed-29766634`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 9871b5713ebdc9e0839826bfbb6e96acffa4c93e88cd0878396cdacc9501f1ba
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
